Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-05

AUTHORS

Shelley R. Salpeter

ABSTRACT

Backgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease. More... »

PAGES

405-414

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005

DOI

http://dx.doi.org/10.2165/00002512-200421060-00005

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044511580

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15084142


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic alpha-2 Receptor Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pulmonary Disease, Chronic Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.415182.b", 
          "name": [
            "Stanford University School of Medicine, Stanford, California, USA", 
            "Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salpeter", 
        "givenName": "Shelley R.", 
        "id": "sg:person.012160071167.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-199142030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021698570", 
          "https://doi.org/10.2165/00003495-199142030-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199207010-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053525213", 
          "https://doi.org/10.2165/00002018-199207010-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050435", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050389605", 
          "https://doi.org/10.1007/s002280050435"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-197600111-00025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045796379", 
          "https://doi.org/10.2165/00003495-197600111-00025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00614551", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009739834", 
          "https://doi.org/10.1007/bf00614551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042256952", 
          "https://doi.org/10.1007/s002280050399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03259844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037870887", 
          "https://doi.org/10.1007/bf03259844"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05", 
    "datePublishedReg": "2004-05-01", 
    "description": "Background\u03b22-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that \u03b22-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of \u03b22-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that \u03b22-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that \u03b22-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of \u03b22-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of \u03b22-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of \u03b2-adrenergic stimulation that \u03b22-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, \u03b22-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether \u03b22-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00002512-200421060-00005", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100990", 
        "issn": [
          "1170-229X", 
          "1179-1969"
        ], 
        "name": "Drugs & Aging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "chronic obstructive pulmonary disease", 
      "adverse cardiovascular events", 
      "obstructive airways disease", 
      "\u03b22-adrenoceptor agonists", 
      "agonist use", 
      "congestive heart failure", 
      "sudden cardiac death", 
      "case-control study", 
      "cardiovascular events", 
      "airway disease", 
      "cardiovascular safety", 
      "heart failure", 
      "cardiac death", 
      "heart rate", 
      "concomitant cardiac conditions", 
      "placebo-controlled trial", 
      "concomitant cardiovascular disease", 
      "management of asthma", 
      "obstructive pulmonary disease", 
      "MethodsA systematic review", 
      "potassium concentration", 
      "pulmonary disease", 
      "agonist treatment", 
      "respiratory tolerance", 
      "cardiac arrest", 
      "asthma attacks", 
      "myocardial infarction", 
      "single doses", 
      "cardiovascular disease", 
      "cardiac conditions", 
      "adrenergic stimulation", 
      "systematic review", 
      "agonists", 
      "disease", 
      "placebo", 
      "asthma", 
      "patients", 
      "risk", 
      "trials", 
      "degree of risk", 
      "death", 
      "treatment", 
      "safety", 
      "bronchodilators", 
      "morbidity", 
      "ischaemia", 
      "infarction", 
      "failure", 
      "arrhythmias", 
      "mortality", 
      "doses", 
      "study", 
      "evidence", 
      "stimulation", 
      "arrest", 
      "events", 
      "causal one", 
      "association", 
      "use", 
      "rate", 
      "new users", 
      "review", 
      "concentration", 
      "management", 
      "effect", 
      "tolerance", 
      "data", 
      "addition", 
      "degree", 
      "attacks", 
      "conditions", 
      "one", 
      "users"
    ], 
    "name": "Cardiovascular Safety of \u03b22-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease", 
    "pagination": "405-414", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044511580"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00002512-200421060-00005"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15084142"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00002512-200421060-00005", 
      "https://app.dimensions.ai/details/publication/pub.1044511580"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_390.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00002512-200421060-00005"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      21 PREDICATES      115 URIs      100 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00002512-200421060-00005 schema:about N3d89ec642dd14c21a6129f4559f870db
2 N445e583b81b2418b97fb5035d93ea8f1
3 N539e17974814414485ef890488d0fe42
4 N6d0ebb18adfa44779f1528ae4cbe3be4
5 N7ca6d86ecae24052bab12773cb14ab8b
6 N93581d5cba8c42b5afeaed024fd53cd9
7 Nd133e7c3ee0440ca93fc55680b9e2459
8 Ne41bd6af3a47412ebf6416b511f67479
9 Nff147d616ed84c5f9c749e3bea018da3
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author Ncf50ba70653543bd94c31677b3427c90
13 schema:citation sg:pub.10.1007/bf00614551
14 sg:pub.10.1007/bf03259844
15 sg:pub.10.1007/s002280050399
16 sg:pub.10.1007/s002280050435
17 sg:pub.10.2165/00002018-199207010-00007
18 sg:pub.10.2165/00003495-197600111-00025
19 sg:pub.10.2165/00003495-199142030-00007
20 schema:datePublished 2004-05
21 schema:datePublishedReg 2004-05-01
22 schema:description Backgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N5ae1acb820674673a34fca97e0e0b6bf
26 N75d504ec318f44b39321e62baa3f11c6
27 sg:journal.1100990
28 schema:keywords MethodsA systematic review
29 addition
30 adrenergic stimulation
31 adverse cardiovascular events
32 agonist treatment
33 agonist use
34 agonists
35 airway disease
36 arrest
37 arrhythmias
38 association
39 asthma
40 asthma attacks
41 attacks
42 bronchodilators
43 cardiac arrest
44 cardiac conditions
45 cardiac death
46 cardiovascular disease
47 cardiovascular events
48 cardiovascular safety
49 case-control study
50 causal one
51 chronic obstructive pulmonary disease
52 concentration
53 concomitant cardiac conditions
54 concomitant cardiovascular disease
55 conditions
56 congestive heart failure
57 data
58 death
59 degree
60 degree of risk
61 disease
62 doses
63 effect
64 events
65 evidence
66 failure
67 heart failure
68 heart rate
69 infarction
70 ischaemia
71 management
72 management of asthma
73 morbidity
74 mortality
75 myocardial infarction
76 new users
77 obstructive airways disease
78 obstructive pulmonary disease
79 one
80 patients
81 placebo
82 placebo-controlled trial
83 potassium concentration
84 pulmonary disease
85 rate
86 respiratory tolerance
87 review
88 risk
89 safety
90 single doses
91 stimulation
92 study
93 sudden cardiac death
94 systematic review
95 tolerance
96 treatment
97 trials
98 use
99 users
100 β2-adrenoceptor agonists
101 schema:name Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease
102 schema:pagination 405-414
103 schema:productId N5964e74b6bca426ba20d38f53aea07b1
104 N6399e7a50ded4079a1cead8c5e1ac24f
105 Nb2d909539aa8407ab8b4b7833e299d91
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044511580
107 https://doi.org/10.2165/00002512-200421060-00005
108 schema:sdDatePublished 2022-08-04T16:55
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N2fcb3c0afcfd4109b9ce008bc17255ad
111 schema:url https://doi.org/10.2165/00002512-200421060-00005
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N2fcb3c0afcfd4109b9ce008bc17255ad schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N3d89ec642dd14c21a6129f4559f870db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Asthma
119 rdf:type schema:DefinedTerm
120 N445e583b81b2418b97fb5035d93ea8f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Randomized Controlled Trials as Topic
122 rdf:type schema:DefinedTerm
123 N539e17974814414485ef890488d0fe42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Case-Control Studies
125 rdf:type schema:DefinedTerm
126 N5964e74b6bca426ba20d38f53aea07b1 schema:name doi
127 schema:value 10.2165/00002512-200421060-00005
128 rdf:type schema:PropertyValue
129 N5ae1acb820674673a34fca97e0e0b6bf schema:issueNumber 6
130 rdf:type schema:PublicationIssue
131 N6399e7a50ded4079a1cead8c5e1ac24f schema:name dimensions_id
132 schema:value pub.1044511580
133 rdf:type schema:PropertyValue
134 N6d0ebb18adfa44779f1528ae4cbe3be4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N75d504ec318f44b39321e62baa3f11c6 schema:volumeNumber 21
138 rdf:type schema:PublicationVolume
139 N7ca6d86ecae24052bab12773cb14ab8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Adrenergic beta-Agonists
141 rdf:type schema:DefinedTerm
142 N93581d5cba8c42b5afeaed024fd53cd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adrenergic alpha-2 Receptor Agonists
144 rdf:type schema:DefinedTerm
145 Nb2d909539aa8407ab8b4b7833e299d91 schema:name pubmed_id
146 schema:value 15084142
147 rdf:type schema:PropertyValue
148 Ncf50ba70653543bd94c31677b3427c90 rdf:first sg:person.012160071167.38
149 rdf:rest rdf:nil
150 Nd133e7c3ee0440ca93fc55680b9e2459 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Cardiovascular Diseases
152 rdf:type schema:DefinedTerm
153 Ne41bd6af3a47412ebf6416b511f67479 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Animals
155 rdf:type schema:DefinedTerm
156 Nff147d616ed84c5f9c749e3bea018da3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Pulmonary Disease, Chronic Obstructive
158 rdf:type schema:DefinedTerm
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
163 schema:name Cardiorespiratory Medicine and Haematology
164 rdf:type schema:DefinedTerm
165 sg:journal.1100990 schema:issn 1170-229X
166 1179-1969
167 schema:name Drugs & Aging
168 schema:publisher Springer Nature
169 rdf:type schema:Periodical
170 sg:person.012160071167.38 schema:affiliation grid-institutes:grid.415182.b
171 schema:familyName Salpeter
172 schema:givenName Shelley R.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38
174 rdf:type schema:Person
175 sg:pub.10.1007/bf00614551 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009739834
176 https://doi.org/10.1007/bf00614551
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/bf03259844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037870887
179 https://doi.org/10.1007/bf03259844
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/s002280050399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042256952
182 https://doi.org/10.1007/s002280050399
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/s002280050435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050389605
185 https://doi.org/10.1007/s002280050435
186 rdf:type schema:CreativeWork
187 sg:pub.10.2165/00002018-199207010-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053525213
188 https://doi.org/10.2165/00002018-199207010-00007
189 rdf:type schema:CreativeWork
190 sg:pub.10.2165/00003495-197600111-00025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045796379
191 https://doi.org/10.2165/00003495-197600111-00025
192 rdf:type schema:CreativeWork
193 sg:pub.10.2165/00003495-199142030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021698570
194 https://doi.org/10.2165/00003495-199142030-00007
195 rdf:type schema:CreativeWork
196 grid-institutes:grid.415182.b schema:alternateName Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA
197 schema:name Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA
198 Stanford University School of Medicine, Stanford, California, USA
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...